Ovid Therapeutics

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$6,272
$130
$76
$173
Gross Profit
6,173
130
76
173
EBITDA
-5,073
-12,409
-10,762
-13,057
EBIT
-5,172
-12,550
-10,922
-13,226
Net Income
-4,684
-10,235
-9,253
-14,006
Net Change In Cash
6,272
130
76
173
Free Cash Flow
-4,774
-10,280
-10,004
-15,003
Cash
28,415
21,136
26,301
15,017
Basic Shares
71,109
71,045
71,010
70,976

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$566
$391
$1,502
$208,383
Gross Profit
566
392
1,502
208,383
EBITDA
-57,772
-57,013
-54,166
124,400
EBIT
-58,385
-57,581
-55,548
124,163
Net Income
-26,433
-52,339
-51,408
122,835
Net Change In Cash
566
391
1,502
208,383
Cost of Revenue
-142,929
117,694
Free Cash Flow
-56,027
-45,918
-56,645
118,422
Cash
26,301
27,041
44,867
187,797
Basic Shares
70,905
70,581
70,425
68,068

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.06
2025-03-31
-$0.14
2024-12-31
-$0.13